Previous close | 29.75 |
Open | 29.71 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 29.20 - 29.73 |
52-week range | 29.20 - 40.48 |
Volume | |
Avg. volume | 2,745,977 |
Market cap | 190.395B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 14.93 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.35 (4.54%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.